<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39450181</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>High prevalence of long COVID in anti-TPO positive euthyroid individuals with strongly elevated SARS-CoV-2-specific T cell responses and moderately raised anti-spike IgG levels 23 months post-infection.</ArticleTitle><Pagination><StartPage>1448659</StartPage><MedlinePgn>1448659</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1448659</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1448659</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), causes post-acute infection syndrome in a surprisingly large number of cases worldwide. This condition, also known as long COVID or post-acute sequelae of COVID-19, is characterized by extremely complex symptoms and pathology. There is a growing consensus that this condition is a consequence of virus-induced immune activation and the inflammatory cascade, with its prolonged duration caused by a persistent virus reservoir.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this cross-sectional study, we analyzed the SARS-CoV-2-specific T cell response against the spike, nucleocapsid, and membrane proteins, as well as the levels of spike-specific IgG antibodies in 51 healthcare workers, categorized into long COVID or convalescent control groups based on the presence or absence of post-acute symptoms. Additionally, we compared the levels of autoantibodies previously identified during acute or critical COVID-19, including anti-dsDNA, anti-cardiolipin, anti-&#x3b2;2-glycoprotein I, anti-neutrophil cytoplasmic antibodies, and anti-thyroid peroxidase (anti-TPO). Furthermore, we analyzed the antibody levels targeting six nuclear antigens within the ENA-6 S panel, as positivity for certain anti-nuclear antibodies has recently been shown to associate not only with acute COVID-19 but also with long COVID. Finally, we examined the frequency of diabetes in both groups. Our investigations were conducted at an average of 18.2 months (convalescent control group) and 23.1 months (long COVID group) after confirmed acute COVID-19 infection, and an average of 21 months after booster vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our results showed significant differences between the two groups regarding the occurrence of acute infection relative to administering the individual vaccine doses, the frequency of acute symptoms, and the T cell response against all structural SARS-CoV-2 proteins. A statistical association was observed between the incidence of long COVID symptoms and highly elevated anti-TPO antibodies based on Pearson's chi-squared test. Although patients with long COVID showed moderately elevated anti-SARS-CoV-2 spike IgG serum antibody levels compared to control participants, and further differences were found regarding the positivity for anti-nuclear antibodies, anti-dsDNA, and HbA1c levels between the two groups, these differences were not statistically significant.</AbstractText><AbstractText Label="DISSCUSSION" NlmCategory="UNASSIGNED">This study highlights the need for close monitoring of long COVID development in patients with elevated anti-TPO titers, which can be indicated by strongly elevated SARS-CoV-2-specific T cell response and moderately raised anti-spike IgG levels even long after the acute infection. However, our results do not exclude the possibility of new-onset thyroid autoimmunity after COVID-19, and further investigations are required to clarify the etiological link between highly elevated anti-TPO titers and long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Matula, Kir&#xe1;ly, Bek&#x151;, G&#xf6;nczi, Z&#xf3;ka, Steinhauser, Uher and V&#xe1;lyi-Nagy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Matula</LastName><ForeName>Zsolt</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory for Experimental Cell Therapy, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kir&#xe1;ly</LastName><ForeName>Vikt&#xf3;ria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Central Laboratory of Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bek&#x151;</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Central Laboratory of Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;nczi</LastName><ForeName>M&#xe1;rton</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Central Laboratory of Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xf3;ka</LastName><ForeName>Andr&#xe1;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Central Laboratory of Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinhauser</LastName><ForeName>R&#xf3;bert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Laboratory of Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uher</LastName><ForeName>Ferenc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory for Experimental Cell Therapy, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;lyi-Nagy</LastName><ForeName>Istv&#xe1;n</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.11.1.8</RegistryNumber><NameOfSubstance UI="D007453">Iodide Peroxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007453" MajorTopicYN="N">Iodide Peroxidase</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IFN&#x3b3; ELISpot assay</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cell responses</Keyword><Keyword MajorTopicYN="N">anti-TPO</Keyword><Keyword MajorTopicYN="N">anti-spike IgG</Keyword><Keyword MajorTopicYN="N">autoantibody characterization</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">long-term immunity</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39450181</ArticleId><ArticleId IdType="pmc">PMC11499158</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1448659</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet (London England). (2022) 400:452&#x2013;61. doi:&#xa0;10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>
Post COVID-19 condition (Long COVID) (2022). Available online at: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition (Accessed 27 May 2024).</Citation></Reference><Reference><Citation>Joshee S, Vatti N, Chang C. Long-term effects of COVID-19. Mayo Clinic Proc. (2022) 97:579&#x2013;99. doi:&#xa0;10.1016/j.mayocp.2021.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.12.017</ArticleId><ArticleId IdType="pmc">PMC8752286</ArticleId><ArticleId IdType="pubmed">35246288</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133&#x2013;46. doi:&#xa0;10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, et al. . SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol. (2023) 24:1616&#x2013;27. doi:&#xa0;10.1038/s41590-023-01601-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. (2023) 23:618&#x2013;34. doi:&#xa0;10.1038/s41577-023-00904-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. (2021) 12:698169. doi:&#xa0;10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo MS, Shafiq M, Fitzek A, Dottermusch M, Altmeppen H, Mohammadi B, et al. . Vagus nerve inflammation contributes to dysautonomia in COVID-19. Acta neuropathologica. (2023) 146:387&#x2013;94. doi:&#xa0;10.1007/s00401-023-02612-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-023-02612-x</ArticleId><ArticleId IdType="pmc">PMC10412500</ArticleId><ArticleId IdType="pubmed">37452829</ArticleId></ArticleIdList></Reference><Reference><Citation>Llados G, Massanella M, Coll-Fernandez R, Rodriguez R, Hernandez E, Lucente G, et al. . Vagus nerve dysfunction in the post-COVID-19 condition: a pilot cross- sectional study. Clin Microbiol infection: Off Publ Eur Soc Clin Microbiol Infect Diseases. (2024) 30:515&#x2013;21. doi:&#xa0;10.1016/j.cmi.2023.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.11.007</ArticleId><ArticleId IdType="pubmed">37984511</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss AB, Greene C, Dayaramani C, Rauchman SH, Stecker MM, De Leon J, et al. . Long COVID, the brain, nerves, and cognitive function. Neurol Int. (2023) 15:821&#x2013;41. doi:&#xa0;10.3390/neurolint15030052</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/neurolint15030052</ArticleId><ArticleId IdType="pmc">PMC10366776</ArticleId><ArticleId IdType="pubmed">37489358</ArticleId></ArticleIdList></Reference><Reference><Citation>Alipoor SD, Mortaz E, Varahram M, Garssen J, Adcock IM. The immunopathogenesis of neuroinvasive lesions of SARS-coV-2 infection in COVID-19 patients. Front neurology. (2021) 12:697079. doi:&#xa0;10.3389/fneur.2021.697079</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.697079</ArticleId><ArticleId IdType="pmc">PMC8363128</ArticleId><ArticleId IdType="pubmed">34393976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rossler A, et al. . Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. (2022) 163:495&#x2013;506.e8. doi:&#xa0;10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Ryder D, Flavell R, Wang Y, Levi J, LaFranchi BH, et al. . Multimodal molecular imaging reveals tissue-based T cell activation and viral RNA persistence for up to 2 years following COVID-19. medRxiv. (2023). doi:&#xa0;10.1101/2023.07.27.23293177</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.27.23293177</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh D, Lim JCT, Fernaindez SB, Joseph CR, Edwards SG, Neo ZW, et al. . Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front Immunol. (2022) 13:939989. doi:&#xa0;10.3389/fimmu.2022.939989</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.939989</ArticleId><ArticleId IdType="pmc">PMC9483160</ArticleId><ArticleId IdType="pubmed">36131932</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Bosurgi L, et al. . Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post- acute sequelae of COVID-19. J Med virology. (2023) 95:e28364. doi:&#xa0;10.1002/jmv.28364</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28364</ArticleId><ArticleId IdType="pmc">PMC9878213</ArticleId><ArticleId IdType="pubmed">36458566</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. . Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect diseases: an Off Publ Infect Dis Soc America. (2023) 76:e487&#x2013;e90. doi:&#xa0;10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, et al. . T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID. medRxiv. (2022). doi:&#xa0;10.2139/ssrn.4299763</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4299763</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. . SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PloS pathogens. (2022) 18:e1010359. doi:&#xa0;10.1371/journal.ppat.1010359</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, et al. . Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. (2024) 25:218&#x2013;25. doi:&#xa0;10.1038/s41590-023-01724-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01724-6</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, et al. . Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity. Nat Commun. (2023) 14:5139. doi:&#xa0;10.1038/s41467-023-40460-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40460-1</ArticleId><ArticleId IdType="pmc">PMC10447583</ArticleId><ArticleId IdType="pubmed">37612310</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Abellan J, Fernandez M, Padilla S, Garcia JA, Agullo V, Lozano V, et al. . Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. (2022) 13:920627. doi:&#xa0;10.3389/fimmu.2022.920627</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.920627</ArticleId><ArticleId IdType="pmc">PMC9451924</ArticleId><ArticleId IdType="pubmed">36090973</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, et al. . High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain behavior immunity. (2021) 93:415&#x2013;9. doi:&#xa0;10.1016/j.bbi.2020.12.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.12.022</ArticleId><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, et al. . Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med. (2021) 2:100288. doi:&#xa0;10.1016/j.xcrm.2021.100288</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100288</ArticleId><ArticleId IdType="pmc">PMC8091032</ArticleId><ArticleId IdType="pubmed">33969321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos AE, Martin-Nares E, Hernandez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. (2021) 10(12):3592. doi:&#xa0;10.3390/cells10123592</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123592</ArticleId><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham EJ, Ren AL, Digby RJ, Norton EJ, Ebrahimi S, Outtrim JG, et al. . Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain: J neurology. (2022) 145:4097&#x2013;107. doi:&#xa0;10.1093/brain/awac321</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac321</ArticleId><ArticleId IdType="pmc">PMC9494359</ArticleId><ArticleId IdType="pubmed">36065116</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter AG, Shields AM, Karim A, Birch D, Faustini SE, Steadman L, et al. . Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol. (2021) 205:99&#x2013;105. doi:&#xa0;10.1111/cei.13623</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13623</ArticleId><ArticleId IdType="pmc">PMC8239842</ArticleId><ArticleId IdType="pubmed">34082475</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, et al. . Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J. (2023) 61: 2200970. doi:&#xa0;10.1183/13993003.00970-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00970-2022</ArticleId><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zeron P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. (2021) 17:315&#x2013;32. doi:&#xa0;10.1038/s41584-021-00608-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00608-z</ArticleId><ArticleId IdType="pmc">PMC8072739</ArticleId><ArticleId IdType="pubmed">33903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. . SARS-CoV-2 infection as a trigger of autoimmune response. Clin Trans science. (2021) 14:898&#x2013;907. doi:&#xa0;10.1111/cts.12953</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12953</ArticleId><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. . Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann rheumatic diseases. (2020) 79:1661&#x2013;3. doi:&#xa0;10.1136/annrheumdis-2020-218009</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218009</ArticleId><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. . New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. (2021) 12:5417. doi:&#xa0;10.1038/s41467-021-25509-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. . Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Trans science. (2020) 13:1077&#x2013;86. doi:&#xa0;10.1111/cts.12805</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Arellano G, Camacho-Ortiz A, Moreno-Arquieta IA, Cardenas-de la Garza JA, Rubio-Torres DC, Garza-Gonzalez E, et al. . Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19. Am J Med Sci. (2023) 365:215&#x2013;7. doi:&#xa0;10.1016/j.amjms.2022.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2022.10.012</ArticleId><ArticleId IdType="pmc">PMC9632263</ArticleId><ArticleId IdType="pubmed">36335994</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano M, Espinosa G, Serrano A, Cervera R. COVID-19 and the antiphospholipid syndrome. Autoimmun Rev. (2022) 21:103206. doi:&#xa0;10.1016/j.autrev.2022.103206</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103206</ArticleId><ArticleId IdType="pmc">PMC9527199</ArticleId><ArticleId IdType="pubmed">36195247</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. . Coagulopathy and antiphospholipid antibodies in patients with covid-19. New Engl J Med. (2020) 382:e38. doi:&#xa0;10.1056/NEJMc2007575</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2007575</ArticleId><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. . Distinguishing features of long COVID identified through immune profiling. Nature. (2023) 623:139&#x2013;48. doi:&#xa0;10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, Furst J, Schulze-Rothe S, Wallukat A, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Trans autoimmunity. (2021) 4:100100. doi:&#xa0;10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, et al. . Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J autoimmunity. (2021) 122:102682. doi:&#xa0;10.1016/j.jaut.2021.102682</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102682</ArticleId><ArticleId IdType="pmc">PMC8214939</ArticleId><ArticleId IdType="pubmed">34214763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ECY, Tyler RE, Johnson D, Koh N, Ong BC, Foo SY, et al. . High frequency of anti-DSG 2 antibodies in post COVID-19 serum samples. J Mol Cell Cardiol. (2022) 170:121&#x2013;3. doi:&#xa0;10.1016/j.yjmcc.2022.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2022.06.006</ArticleId><ArticleId IdType="pmc">PMC9233549</ArticleId><ArticleId IdType="pubmed">35764120</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ebinger JE, Mostafa R, Budde P, Gajewski J, Walker B, et al. . Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. J Trans Med. (2021) 19:524. doi:&#xa0;10.1186/s12967-021-03184-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03184-8</ArticleId><ArticleId IdType="pmc">PMC8716184</ArticleId><ArticleId IdType="pubmed">34965855</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. (2023) 41:1783&#x2013;90. doi:&#xa0;10.1016/j.vaccine.2023.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh NT, Jodicke AM, Catala M, Mercade-Besora N, Hayati S, Lupattelli A, et al. . Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway. Lancet Respir Med. (2024) 12:e33&#x2013;e4. doi:&#xa0;10.1016/S2213-2600(24)00082-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(24)00082-1</ArticleId><ArticleId IdType="pubmed">38614106</ArticleId></ArticleIdList></Reference><Reference><Citation>Catala M, Mercade-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, et al. . The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. (2024) 12:225&#x2013;36. doi:&#xa0;10.1016/S2213-2600(23)00414-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Voyer T, Parent AV, Liu X, Cederholm A, Gervais A, Rosain J, et al. . Autoantibodies against type I IFNs in humans with alternative NF-kappaB pathway deficiency. Nature. (2023) 623:803&#x2013;13. doi:&#xa0;10.1038/s41586-023-06717-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06717-x</ArticleId><ArticleId IdType="pmc">PMC10665196</ArticleId><ArticleId IdType="pubmed">37938781</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari A, Hadizadeh A, Amiri M, Najafi NN, Shahriari Z, Jamialahmadi T, et al. . Role of autoantibodies targeting interferon type 1 in COVID-19 severity: A systematic review and meta-analysis. J Trans autoimmunity. (2023) 7:100219. doi:&#xa0;10.1016/j.jtauto.2023.100219</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2023.100219</ArticleId><ArticleId IdType="pmc">PMC10587724</ArticleId><ArticleId IdType="pubmed">37868109</ArticleId></ArticleIdList></Reference><Reference><Citation>Casciola-Rosen L, Thiemann DR, Andrade F, Trejo-Zambrano MI, Leonard EK, Spangler JB, et al. . IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. (2022) 7(9): e158362. doi:&#xa0;10.1172/jci.insight.158362</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.158362</ArticleId><ArticleId IdType="pmc">PMC9090251</ArticleId><ArticleId IdType="pubmed">35349483</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari A, Hadizadeh A, Islampanah M, Salavati Nik E, Atkin SL, Sahebkar A. COVID-19, G protein-coupled receptor, and renin-angiotensin system autoantibodies: Systematic review and meta-analysis. Autoimmun Rev. (2023) 22:103402. doi:&#xa0;10.1016/j.autrev.2023.103402</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103402</ArticleId><ArticleId IdType="pubmed">37490975</ArticleId></ArticleIdList></Reference><Reference><Citation>Perilli L, Fetta M, Capponi M, Guido CA, Grosso S, Iannetti P, et al. . Peripheral nervous system involvement in SARS-CoV-2 infection: a review of the current pediatric literature. Front neurology. (2023) 14:1134507. doi:&#xa0;10.3389/fneur.2023.1134507</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2023.1134507</ArticleId><ArticleId IdType="pmc">PMC10249431</ArticleId><ArticleId IdType="pubmed">37305745</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter MM, Martins TA, Kulsvehagen L, Possnecker E, Duchemin W, Hogan S, et al. . Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study. Nat Commun. (2022) 13:6777. doi:&#xa0;10.1038/s41467-022-34068-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34068-0</ArticleId><ArticleId IdType="pmc">PMC9645766</ArticleId><ArticleId IdType="pubmed">36351919</ArticleId></ArticleIdList></Reference><Reference><Citation>Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, et al. . Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. (2022) 8:eabn3777. doi:&#xa0;10.1126/sciadv.abn3777</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abn3777</ArticleId><ArticleId IdType="pmc">PMC9544317</ArticleId><ArticleId IdType="pubmed">36206332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. . Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Trans Med. (2020) 12(570): eabd3876. doi:&#xa0;10.1126/scitranslmed.abd3876</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Banjongjit A, Thammathiwat T, Townamchai N, Kanjanabuch T. SARS-CoV-2 infection associated with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN): a systematic review and two case reports. J nephrology. (2024) 37:53&#x2013;63. doi:&#xa0;10.1007/s40620-023-01777-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-023-01777-8</ArticleId><ArticleId IdType="pubmed">37930464</ArticleId></ArticleIdList></Reference><Reference><Citation>Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N. ANCA-associated vasculitis after COVID-19. Rheumatol Int. (2021) 41:1523&#x2013;9. doi:&#xa0;10.1007/s00296-021-04914-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04914-3</ArticleId><ArticleId IdType="pmc">PMC8184057</ArticleId><ArticleId IdType="pubmed">34100115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossini A, Cassibba S, Perticone F, Benatti SV, Venturelli S, Carioli G, et al. . Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study. Front endocrinology. (2023) 14:1126683. doi:&#xa0;10.3389/fendo.2023.1126683</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1126683</ArticleId><ArticleId IdType="pmc">PMC10031076</ArticleId><ArticleId IdType="pubmed">36967795</ArticleId></ArticleIdList></Reference><Reference><Citation>Alphan Uc Z, Yagci P, Adibelli Z, Duran C. The spectrum of thyroid function tests and autoantibodies during hospitalization and after six months of discharge in COVID-19 patients: does COVID-19 trigger autoimmunity? Endocrine Res. (2023) 48:44&#x2013;54. doi:&#xa0;10.1080/07435800.2023.2188086</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07435800.2023.2188086</ArticleId><ArticleId IdType="pubmed">36883908</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark M, Kroger CJ, Tisch RM. Type 1 diabetes: A chronic anti-self-inflammatory response. Front Immunol. (2017) 8:1898. doi:&#xa0;10.3389/fimmu.2017.01898</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01898</ArticleId><ArticleId IdType="pmc">PMC5743904</ArticleId><ArticleId IdType="pubmed">29312356</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. (2016) 23:87. doi:&#xa0;10.1186/s12929-016-0303-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-016-0303-y</ArticleId><ArticleId IdType="pmc">PMC5135788</ArticleId><ArticleId IdType="pubmed">27912756</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The role of viral infections in the onset of autoimmune diseases. Viruses. (2023) 15(3): 782. doi:&#xa0;10.3390/v15030782</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030782</ArticleId><ArticleId IdType="pmc">PMC10051805</ArticleId><ArticleId IdType="pubmed">36992490</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding JL, Oviedo SA, Ali MK, Ofotokun I, Gander JC, Patel SA, et al. . The bidirectional association between diabetes and long-COVID-19 - A systematic review. Diabetes Res Clin practice. (2023) 195:110202. doi:&#xa0;10.1016/j.diabres.2022.110202</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2022.110202</ArticleId><ArticleId IdType="pmc">PMC9727969</ArticleId><ArticleId IdType="pubmed">36496030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>